More info
Assay Range | 62.5--4000 pg/mL |
Sensitivity | 5.0 pg/mL |
Size | 96T |
Storage | Store at 2 - 8ºC. Keep reconstituted standard and detection Ab at -20 ºC |
Assay Principle | Sandwich ELISA |
Sample volume | 100 µL final volume, dilution factor varies on samples |
Detection Method | Chromogenic |
Kit Components
1. Recombinant Rat IGF-1 standard: 2 vials
2. One 96-well plate precoated with anti-Rat IGF-1 Ab
3. Sample diluent buffer: 12 mL - 1
4. Detection antibody: 130 µL, dilution 1:100
5. Streptavidin-HRP: 130 µL, dilution 1:100
6. Antibody diluent buffer: 12 mL x1
7. Streptavidin-HRP diluent buffer: 12 mL x1
8. TMB developing agent: 10 mL x1
9. Stop solution: 10 mL x1.
10. Washing solution (20x): 25 mL x1.
Background
Insulin-like growth factor 1 (IGF-1), also known as somatomedin C, is a protein encoded by the IGF1 gene in humans and other mammals. Human IGF-1 is 70% identical to human IGF-II and shares 50% sequence identity with the A- and B-chains of human insulin. Mature mouse IGF-I is a non-glycosylated, 70 amino acid (aa) secreted polypeptide that is derived from either a 153 aa or a 159 aa preproprotein. It shares 99% and 94% aa sequence identity with rat and human IGF-I, respectively. The principal functions of IGF-1 are to regulate the activities of growth hormone. It plays an important role in prenatal development, growth to adulthood, and metabolic control. It induces amino acid uptake, protein synthesis, and glucose utilization. It also is an important mitogen and regulator of the cell cycle and apoptosis.
IGF-1 binds to at least two cell surface receptors: the IGF-1 receptor (IGF1R) and the insulin receptor. IGF1R bound to IGF-1 with high affinity is a major mediator of IFG-1 signaling pathways. It has been demonstrated that the insulin/IGF-1-like receptor pathways contribute a lot to the biological aging process in many organisms. It is reported that reduced levels of IGF-1 result in decreased growth of existing cancer cells. Dietary interventions and modifications can down regulate IGF-1 activities and has been associated with lower risk of cancer. Currently, Mecasermin, a synthetic analog of IGF-1, has been approved for the treatment of growth failure.